


Treatment of patients with Nodular lymphocyte predominant Hodgkin lymphoma at diagnosis can improve progression-free survival, compared to watchful waiting

314 patients

82.5% had early-stage nodular lymphocyte predominant Hodgkin lymphoma



watchful waiting (36.3%)



radiotherapy (20.1%)

rituximab (8.9%)

chemotherapy or
immuno-chemotherapy (21.7%)

combined modality treatment (12.7%)

radiotherapy and rituximab (0.3%)



Early treatment with chemotherapy or radiotherapy
(but not rituximab alone)
reduces the risk of progression (**p=0.0002**)